These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32284325)

  • 1. Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer.
    Shrestha N; Bland AR; Bower RL; Rosengren RJ; Ashton JC
    J Pharmacol Exp Ther; 2020 Jul; 374(1):134-140. PubMed ID: 32284325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer.
    Shrestha N; Nimick M; Dass P; Rosengren RJ; Ashton JC
    Sci Rep; 2019 Dec; 9(1):18842. PubMed ID: 31827192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
    Sun Y; Nowak KA; Zaorsky NG; Winchester CL; Dalal K; Giacalone NJ; Liu N; Werner-Wasik M; Wasik MA; Dicker AP; Lu B
    Mol Cancer Ther; 2013 May; 12(5):696-704. PubMed ID: 23443800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
    Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.
    Dai Y; Wei Q; Schwager C; Moustafa M; Zhou C; Lipson KE; Weichert W; Debus J; Abdollahi A
    Radiother Oncol; 2015 Feb; 114(2):173-81. PubMed ID: 25592111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer.
    Bland AR; Bower RL; Nimick M; Hawkins BC; Rosengren RJ; Ashton JC
    Eur J Pharmacol; 2019 Dec; 865():172749. PubMed ID: 31654622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomes from Irradiated Nonsmall Cell Lung Cancer Cells Reduced Sensitivity of Recipient Cells to Anaplastic Lymphoma Kinase Inhibitors.
    Wu H; Zeng C; Ye Y; Liu J; Mu Z; Xie Y; Chen B; Nong Q; Wu D
    Mol Pharm; 2018 May; 15(5):1892-1900. PubMed ID: 29595984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
    Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
    Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
    Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
    J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of metformin in EML
    Bland AR; Shrestha N; Bower RL; Rosengren RJ; Ashton JC
    Biochem Pharmacol; 2021 Jan; 183():114345. PubMed ID: 33227290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
    Wang W; Sun X; Hui Z
    Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK.
    Liang C; Zhang N; Tan Q; Liu S; Luo R; Wang Y; Shi Y; Han X
    Curr Cancer Drug Targets; 2019; 19(8):655-665. PubMed ID: 30381078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
    Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
    Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC.
    Dai Y; Wei Q; Schwager C; Hanne J; Zhou C; Herfarth K; Rieken S; Lipson KE; Debus J; Abdollahi A
    Radiat Oncol; 2018 Jan; 13(1):1. PubMed ID: 29304828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
    Tanizaki J; Okamoto I; Takezawa K; Sakai K; Azuma K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Janne PA; Nakagawa K
    Br J Cancer; 2012 Feb; 106(4):763-7. PubMed ID: 22240786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
    Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.